Physician

Mitchell S. Fineman, MD

According to 2025 Medicare claims, Mitchell Fineman, MD (NPI: 1013965276) practices ophthalmology in the Philadelphia, PA market, with the plurality of this provider's patient population coming from Delaware, PA. This provider's primary affiliated billing organization is RETINOVITREOUS ASSOCIATES LTD (NPI: 1659326452; TIN: 231932869) and primary practice location at 19073-2304.

Fineman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 2,285 traditional Medicare patients, billed 55,183 HCPCS/CPT codes, and received $8,099,195 in Medicare payments. The top billing code was Q5128 (Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg). Part D data shows 379 prescription claims across 146 beneficiaries totaling $17,671 in drug costs, led by Prednisolone Acetate (Prednisolone Acetate). Open Payments data shows 63 records totaling $188,347. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $33,326 and ending at $17,671. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	2,199	23,674	$5,434,790
2016	2,221	25,849	$5,594,035
2017	2,146	25,930	$5,578,186
2018	2,473	31,325	$6,522,589
2019	2,428	32,968	$6,913,697
2020	2,000	30,621	$6,575,543
2021	2,120	31,738	$6,799,599
2022	2,166	34,175	$6,876,411
2023	2,244	39,457	$7,187,174
2024	2,285	55,183	$8,099,195

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	160	393	$33,326
2016	167	452	$34,535
2017	146	385	$30,339
2018	150	358	$41,696
2019	155	384	$41,132
2020	129	353	$52,300
2021	138	353	$27,584
2022	132	309	$22,343
2023	126	310	$32,296
2024	146	379	$17,671

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
Q5128	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	462	13,985	$181
67028	Injection of drug into eye	836	4,230	$111
92014	Established patient complete exam of visual system	1,036	1,191	$94
92012	Established patient problem focused exam of visual system	1,087	3,178	$70
92134	Imaging of retina	2,179	6,260	$33

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Prednisolone Acetate	Prednisolone Acetate	142	5,739	$6,471
Difluprednate	Difluprednate	18	438	$1,689
Atropine Sulfate	Atropine Sulfate	14	807	$660
Ofloxacin	Ofloxacin	49	1,183	$532
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	14	878	$518

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$53	Boston Scientific Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	62	$188,294	Apellis Pharmaceuticals, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mitchell S. Fineman, MD?

Tedicare shows public-source Medicare data for Mitchell S. Fineman, MD (NPI 1013965276), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mitchell S. Fineman, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mitchell S. Fineman, MD?

Mitchell S. Fineman, MD is linked to RETINOVITREOUS ASSOCIATES LTD (billing NPI 1659326452) in the available physician profile data.

Does Mitchell S. Fineman, MD have Open Payments data?

Mitchell S. Fineman, MD has 63 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.